R
Robert P. Hasserjian
Researcher at Harvard University
Publications - 343
Citations - 21234
Robert P. Hasserjian is an academic researcher from Harvard University. The author has contributed to research in topics: Medicine & Myeloid leukemia. The author has an hindex of 53, co-authored 284 publications receiving 16118 citations. Previous affiliations of Robert P. Hasserjian include Hammersmith Hospital & Partners HealthCare.
Papers
More filters
Journal ArticleDOI
Philadelphia chromosome-positive acute myeloid leukemia: a rare aggressive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis.
Chad P. Soupir,Jo Anne Vergilio,Paola Dal Cin,Alona Muzikansky,Hagop M. Kantarjian,Dan Jones,Robert P. Hasserjian +6 more
TL;DR: Patients with Ph+ AML were less likely to have splenomegaly or peripheral basophilia and had lower bone marrow cellularity and myeloid/erythroid ratios than patients with CML-MBC and additional specific cytogenetic abnormalities that typically occur in CML -MBC were less common in Ph+AML.
Journal ArticleDOI
Modulated expression of notch1 during thymocyte development
TL;DR: Analysis of patterns of expression of NOTCH1 protein in thymocytes of the developing and mature thymus and flow cytometric analysis and immunohistochemical staining of flow-sorted cells indicate a dynamic pattern of Notch1 expression during T-cell differentiation and suggest that downregulation of NOTch1 may be required for maturation of cortical thymocyte.
Journal ArticleDOI
Clinicopathologic analysis of follicular lymphoma occurring in children.
Robert B. Lorsbach,Dominic Shay-Seymore,Jennifer Moore,Peter M. Banks,Robert P. Hasserjian,John T. Sandlund,Frederick G. Behm +6 more
TL;DR: Findings indicate that, in contrast to adult follicular lymphomas, dysregulated bcl-2 expression does not play a significant pathogenetic role in most pediatric follicularymphoma, however, bcl -2 expression in pediatric follicle lymphoma identifies a subset of patients in whom disease is often disseminated at clinical presentation and is more refractory to combination chemotherapy.
Journal ArticleDOI
Sequence-Based Discovery of Bradyrhizobium enterica in Cord Colitis Syndrome
Ami B. Bhatt,Samuel S. Freeman,Alex F. Herrera,Chandra Sekhar Pedamallu,Chandra Sekhar Pedamallu,Dirk Gevers,Fujiko Duke,Fujiko Duke,Joonil Jung,Monia Michaud,Bruce David Walker,Sally U. Young,Ashlee M. Earl,Aleksandar Kostic,Aleksandar Kostic,Akinyemi I. Ojesina,Akinyemi I. Ojesina,Robert P. Hasserjian,Karen K. Ballen,Yi Bin Chen,Gabriela S. Hobbs,Joseph H. Antin,Robert J. Soiffer,Lindsey R. Baden,Wendy S. Garrett,Wendy S. Garrett,Jason L. Hornick,Francisco M. Marty,Matthew Meyerson,Matthew Meyerson +29 more
TL;DR: In this article, the authors performed shotgun DNA sequencing on four archived, paraffin-embedded endoscopic colon-biopsy specimens obtained from two patients with cord colitis.
Journal ArticleDOI
α-CTLA-4 mAb-associated Panenteritis: A Histologic and Immunohistochemical Analysis
Darryl A. Oble,Mari Mino-Kenudson,Jeff Goldsmith,F. Stephen Hodi,Rania M. Seliem,Glenn Dranoff,Martin C. Mihm,Robert P. Hasserjian,Gregory Y. Lauwers +8 more
TL;DR: It is concluded that the panenteritis associated with injection of α-CTLA-4 mAbs demonstrates histology resembling autoimmune enteropathy, and it is suspected that the increased number of regulatory T cells in the gastrointestinal mucosa may play a role in the pathogenicity.